The beta 1 integrin, very late activation antigen-4 on human neutrophils can contribute to neutrophil migration through connective tissue fibroblast barriers.
Polymorphonuclear leucocyte (PMNL) accumulation in extravascular tissues and inflammatory exudates is dependent on their migration through blood vessel endothelium and then through connective tissue. Previously we utilized a barrier of human synovial and dermal fibroblasts (HSF or HDF) grown on microporous filters, as a model of PMNL migration through connective tissue. Those studies showed that beta 2 (CD18) and the beta 1 integrins, very late activation antigen-5 (VLA-5) and VLA-6, in part mediate this PMNL migration. Here we report that VLA-4, which can also be expressed at low levels on activated PMNL, is also involved in PMNL migration induced by C5a through fibroblast (HSF and HDF) barriers, because monoclonal antibody (mAb) to VLA-4 significantly inhibited (by 20-30%) PMNL migration. Blocking the function of CD18, VLA-5 or VLA-6 was not required for detection of the VLA-4-mediated migration. Combination treatment with mAb to VLA-4 and with mAb to VLA-5 or to VLA-6 further inhibited PMNL migration, irrespective of whether CD11/CD18 mechanisms were blocked with anti-CD18 mAb or not. Treatment of PMNL with a peptide based on the VLA-4-binding domain in the CS-1 fragment of fibronectin, but not a control peptide, inhibited PMNL migration to a comparable extent to treatment with mAb to VLA-4. A low level of VLA-4 was expressed on C5a-activated PMNL, detected by immunofluorescence flow cytometry. These results suggest that VLA-4 can be mobilized by human peripheral blood PMNL and can, in addition to VLA-5, VLA-6 and CD11/CD18 integrins, mediate PMNL migration through connective tissue. This is in marked contrast to PMNL transendothelial migration, where beta 1 integrins appear to play no significant role.
Gao
J X
JX
Department of Pediatrics and Microbiology, Dalhousie University, Halifax, NS, Canada.
Issekutz
A C
AC
D018821:CD18 Antigens / Q000276:immunology; D002352:Carrier Proteins / Q000494:pharmacology; D018929:Cell Culture Techniques; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D003238:Connective Tissue / Q000276:immunology*; D005347:Fibroblasts / Q000276:immunology; D006801:Humans; D039041:Integrin alpha4beta1; D016023:Integrins / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology*; D009842:Oligopeptides / Q000494:pharmacology; D016201:Receptors, Lymphocyte Homing / Q000276:immunology*; D016029:Receptors, Very Late Antigen / Q000276:immunology* / Q000378:metabolism; D012867:Skin / Q000276:immunology; D013583:Synovial Membrane / Q000276:immunology
D018821:CD18 Antigens; D002352:Carrier Proteins; D039041:Integrin alpha4beta1; D016023:Integrins; D009842:Oligopeptides; D016201:Receptors, Lymphocyte Homing; D016029:Receptors, Very Late Antigen; C094697:glutamyl-isoleucyl-leucyl-aspartyl-valine